Zai gains China rights to three MacroGenics immuno-oncology compounds

Zai Lab Ltd. (NASDAQ:ZLAB) bulked up its cancer pipeline Thursday by in-licensing Chinese rights to three immuno-oncology compounds from MacroGenics Inc. (NASDAQ:MGNX), including margetuximab, an Fc optimized

Read the full 272 word article

User Sign In